Predictive factors of new CAM use for Korean patients with RA (n = 1867).
| Factor | Adjusted OR | 95% CI | p |
|---|---|---|---|
| Sex | |||
| Male | 1.00 (ref) | ||
| Female | 1.89 | 1.13–3.14 | 0.01 |
| Age at enrollment, yrs | |||
| ≥ 65 | 1.00 (ref) | ||
| ≥ 40 to < 65 | 1.01 | 0.67–1.51 | 0.98 |
| < 40 | 1.27 | 0.68–2.36 | 0.45 |
| Disease duration, yrs | |||
| > 10 | 1.00 (ref) | ||
| > 5 to ≤ 10 | 1.26 | 0.83–1.92 | 0.28 |
| > 1 to ≤ 5 | 1.04 | 0.69–1.59 | 0.84 |
| ≤ 1 | 1.56 | 0.97–2.49 | 0.06 |
| Education | |||
| ≥ High school | 1.00 (ref) | ||
| ≤ Middle school | 1.11 | 0.79–1.58 | 0.55 |
| Household type | |||
| Nuclear family | 1.00 (ref) | ||
| Extended family | 1.78 | 1.08–2.95 | 0.02 |
| Couple | 1.55 | 1.07–2.24 | 0.02 |
| Single | 1.22 | 0.71–2.09 | 0.48 |
| HAQ | 1.38 | 0.99–1.83 | 0.05 |
| Patient pain VAS, cm | 1.01 | 0.93–1.10 | 0.83 |
| Patient’s GH VAS, cm | 0.97 | 0.89–1.06 | 0.49 |
| DAS28-ESR | |||
| < 2.6 | 1.00 (ref) | ||
| ≥ 2.6 to < 3.2 | 1.08 | 0.65–1.77 | 0.78 |
| ≥ 3.2 to ≤ 5.1 | 1.05 | 0.69–1.60 | 0.83 |
| > 5.1 | 0.87 | 0.45–1.66 | 0.67 |
| Medication | |||
| MTX | 0.95 | 0.63–1.42 | 0.80 |
| Biologics | 0.59 | 0.29–1.21 | 0.15 |
| History of drug side effects | |||
| Yes | 1.15 | 0.83–1.59 | 0.39 |
| Comorbidity | |||
| CVD | 0.31 | 0.09–1.03 | 0.06 |
| HTN | 0.99 | 0.70–1.44 | 1.00 |
| Gastrointestinal disease | 1.17 | 0.82–1.68 | 0.39 |
| Depression | 3.52 | 1.65–7.50 | < 0.01 |
Chi-square goodness-of-fit = 9.63 (p = 0.29) and C-statistic = 0.63. In the case of continuous variables such as HAQ, Patient pain VAS, and Patient’s GH VAS, the presented OR indicated the odds per unit. CAM: complementary and alternative medicine; RA: rheumatoid arthritis; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; GH: global health; DAS28: Disease Activity Score in 28 joints: ESR: erythrocyte sedimentation rate; MTX: methotrexate; CVD: cardiovascular disease; HTN: hypertension; ref: reference.